UY37774A - Compuestos 5-cianoindol sustituidos y usos de los mismos - Google Patents
Compuestos 5-cianoindol sustituidos y usos de los mismosInfo
- Publication number
- UY37774A UY37774A UY0001037774A UY37774A UY37774A UY 37774 A UY37774 A UY 37774A UY 0001037774 A UY0001037774 A UY 0001037774A UY 37774 A UY37774 A UY 37774A UY 37774 A UY37774 A UY 37774A
- Authority
- UY
- Uruguay
- Prior art keywords
- cyanoindol
- substituted
- compounds
- same
- lsd1
- Prior art date
Links
- YHYLDEVWYOFIJK-UHFFFAOYSA-N 1h-indole-5-carbonitrile Chemical class N#CC1=CC=C2NC=CC2=C1 YHYLDEVWYOFIJK-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Abstract
Se proporciona un compuesto de la Fórmula (I), o una sal farmacéuticamente aceptable del mismo, el cual se ha mostrado es útil para el tratamiento de enfermedades o trastornos mediado por lisina (K) -desmetilasa específica 1A (LSD1) donde R1, R2, R3, R4 y R5 son como se definen en la presente
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2017089020 | 2017-06-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY37774A true UY37774A (es) | 2019-01-31 |
Family
ID=63036268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001037774A UY37774A (es) | 2017-06-19 | 2018-06-15 | Compuestos 5-cianoindol sustituidos y usos de los mismos |
Country Status (8)
Country | Link |
---|---|
US (1) | US10604502B2 (es) |
EP (1) | EP3642195A1 (es) |
JP (1) | JP2020524148A (es) |
CN (1) | CN111032641A (es) |
AR (1) | AR112168A1 (es) |
TW (1) | TW201904942A (es) |
UY (1) | UY37774A (es) |
WO (1) | WO2018234978A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113631164A (zh) | 2019-03-20 | 2021-11-09 | 奥莱松基因组股份有限公司 | 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法 |
JP2022525679A (ja) | 2019-03-20 | 2022-05-18 | オリソン ヘノミクス,ソシエダ アノニマ | 境界性パーソナリティ障害の処置方法 |
CN112608243A (zh) * | 2020-12-15 | 2021-04-06 | 深圳市华先医药科技有限公司 | 一种反式-3-氨基丁醇的合成方法 |
WO2022204235A1 (en) * | 2021-03-23 | 2022-09-29 | Nido Biosciences, Inc. | Bicyclic compounds as androgen receptor modulators |
EP4319732A1 (en) | 2021-04-08 | 2024-02-14 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors for treating myeloid cancers |
CN116102533A (zh) * | 2021-11-11 | 2023-05-12 | 中国科学院上海药物研究所 | 一种芳杂环类化合物及其应用 |
WO2023217758A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
WO2023217784A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
WO2023233130A1 (en) | 2022-05-30 | 2023-12-07 | AdoRx Therapeutics Limited | Cd73 inhibitor compounds |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
BR112015014968A2 (pt) * | 2012-12-21 | 2017-07-11 | Quanticel Pharmaceuticals Inc | inibidores de histona-desmetilase |
JP2017508798A (ja) * | 2014-03-07 | 2017-03-30 | ザ ジョンズ ホプキンス ユニバーシティ | ヒストンリジン特異的デメチラーゼ(lsd1)およびヒストンデアセチラーゼ(hdac)の阻害剤 |
WO2017149463A1 (en) * | 2016-03-01 | 2017-09-08 | Novartis Ag | Cyano-substituted indole compounds and uses thereof as lsd1 inhibitors |
JP2019532953A (ja) * | 2016-09-30 | 2019-11-14 | ノバルティス アーゲー | 増強された有効性を有する免疫エフェクター細胞治療 |
EP3551178A1 (en) * | 2016-12-09 | 2019-10-16 | Constellation Pharmaceuticals, Inc. | Markers for personalized cancer treatment with lsd1 inhibitors |
-
2018
- 2018-06-15 UY UY0001037774A patent/UY37774A/es not_active Application Discontinuation
- 2018-06-18 AR ARP180101697A patent/AR112168A1/es unknown
- 2018-06-19 EP EP18746287.4A patent/EP3642195A1/en not_active Withdrawn
- 2018-06-19 CN CN201880051820.XA patent/CN111032641A/zh active Pending
- 2018-06-19 TW TW107121031A patent/TW201904942A/zh unknown
- 2018-06-19 US US16/012,468 patent/US10604502B2/en active Active
- 2018-06-19 JP JP2019569866A patent/JP2020524148A/ja active Pending
- 2018-06-19 WO PCT/IB2018/054481 patent/WO2018234978A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20190023684A1 (en) | 2019-01-24 |
EP3642195A1 (en) | 2020-04-29 |
JP2020524148A (ja) | 2020-08-13 |
CN111032641A (zh) | 2020-04-17 |
US10604502B2 (en) | 2020-03-31 |
WO2018234978A1 (en) | 2018-12-27 |
AR112168A1 (es) | 2019-09-25 |
TW201904942A (zh) | 2019-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY37774A (es) | Compuestos 5-cianoindol sustituidos y usos de los mismos | |
DOP2017000149A (es) | Compuestos de triazolopirimidina y usos de los mismos | |
CL2019001744A1 (es) | Derivados de benzoxazol como inmunomoduladores. | |
CO2017000399A2 (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos | |
CR20170237A (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
CO2019000932A2 (es) | Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica. | |
AR110747A1 (es) | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo | |
ECSP18073726A (es) | Inhibidores del enlace proteína-proteína de wdr5 | |
CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
CL2020000886A1 (es) | Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih. | |
CU24411B1 (es) | Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos | |
PE20151542A1 (es) | Compuestos de tetrahidropirrolotiazina | |
DOP2015000201A (es) | Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos | |
UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
AR090241A1 (es) | INHIBIDORES DE LA b-SECRETASA | |
DOP2017000034A (es) | Compuestos de imidazopiridazina | |
EA201791802A1 (ru) | СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС | |
UY36145A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
PE20151718A1 (es) | Compuestos piridinilpirazoloquinolina | |
CO2020010306A2 (es) | Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado. | |
CU20170153A7 (es) | Compuestos tricíclicos útiles como inhibidores de la fosfodiesterasa | |
UY36228A (es) | Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen | |
CO2019001644A2 (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
UY37641A (es) | Compuestos de isoxazol carboxamida y usos de los mismos | |
ECSP17071769A (es) | Derivados de aminohidrotiazina fusionados con tetrahidrofurano los cuales son útiles en el tratamiento de la enfermedad de alzheimer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20231110 |